Tags: Intellectual Property
IP Update | Saisie: recent developments
Join our IP experts Kirian Claeyé and Isabelle Vermeyen for our IP Update on Thursday 28 September from 13:30 – 14:30.
Language(s) before the UPC Belgian Local Division
This morning, on 30 May 2023, Belgium’s declaration regarding the language(s) of the proceedings before the Belgian Local Division was published in the Belgian State Gazette. We have inserted a link at the end of this blog to the relevant page of the Belgian State Gazette. Here are the key take-aways.
ALTIUS Webinars | IP Update
Although a company has a great deal of freedom to develop or select the products and services it wishes to market as well as the way it would like to present and/or promote them, such freedom is not absolute. Such freedom is subject to limitations and is often balanced against other freedoms and rights of others, including intellectual property rights and fair competition principles.
The recent tax and social security reforms on copyright income: what employers need to know
Following an intense debate, the legislator introduced a new tax scheme applicable to copyright income. Main raison for this initiative is the assumed abuse of the until then beneficial tax regime. Under the amended tax rules, employees still qualify for the special tax scheme, but with a stricter legal framework.
WEBINAR VIDEO | IP license agreements: common pitfalls and key issues
In this webinar, Bart Bollen and Bregt Raus share with you the traps and mistakes that companies make when licensing their intellectual property.
IP license agreements: common pitfalls and key issues
Learn how to identify and address key issues in licensing agreements to avoid legal headaches!
Trademark protection in Web 3.0: Lessons from the Hermès vs. MetaBirkins case
On 8 February 2023, a New York jury delivered its long-awaited verdict in a case brought by the French luxury brand Hermès, against the artist Mason Rothschild.
When are IP holders liable for enforcing a later invalidated IP right?
At this IP Update, our IP specialists, Christophe Ronse and Kirian Claeyé, will discuss under what circumstances IP holders may be held liable for enforcing a later invalidated IP right.
WEBINAR VIDEO | What do the CJEU’s decisions on parallel trade of medicines mean for your company?
At this additional Christmas edition, the IP specialists in our Life Sciences team discuss the CJEU’s latest decisions on the parallel trade of medicines, and what these decisions mean in practice for your company.
What do the CJEU’s decisions on parallel trade of medicines mean for your company?
At this additional Christmas edition, the IP specialists in our Life Sciences team will discuss the CJEU’s latest decisions on the parallel trade of medicines, and what these decisions mean in practice for your company.
Are parallel importers necessarily allowed to rebox medicines in case of visible traces from ATDs? The CJEU says NO
Pharmaceutical companies are obliged to affix an anti-tampering device (‘ATD’) on prescription-only medicines to enable verification of whether a medicine’s packaging has been tampered with. Parallel importers argue that this results in an overarching objective necessity to ‘rebox’ such medicines.
Can parallel importers (re)brand generic medicines? The CJEU limits the ‘room for manoeuvre’
If a branded medicine and its generic version are put on the EEA market by economically-linked undertakings, is a parallel importer then allowed to rebrand and repackage the imported generic version as the branded reference medicine? After the Brussels Court of Appeal had referred questions on this issue for a preliminary ruling two years ago, the CJEU has now clarified the limits.